Skip to content

Savara SVRA Return on equity

Return on equity at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
-209.8%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
100.7%+60.3pp
Innoviva, Inc. logo
Innoviva, Inc.INVA
29.1%
Theravance Biopharma logo
Theravance BiopharmaTBPH
50.2%+36.2pp
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
18.8%+15.6pp
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
-34.2%+0.9pp

Other financials

Income statement

See full
Revenue-
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.19B+236%
Enterprise value$1.19B+224%
P/S4,648.7×

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Debt / equity0.2×0.0×
Current ratio13.5×-1.4×

Where this comes from

Calculated from Savara’s reported figures.

Based on trailing twelve months.

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Savara's return on equity?
Savara (SVRA) reported return on equity of -80% in Q1 2026.
How has Savara's return on equity changed year-over-year?
Savara's return on equity decreased by 5.5% year-over-year, from -75.8% to -80%.
What is the long-term trend for Savara's return on equity?
Over 5 years (2020 to 2025), Savara's return on equity has grown at a 1.2% compound annual growth rate (CAGR), from -59.7% to -63.5%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.